Is this a good thing? reading about the tox requirements: Toxicology studies with specific monoclonal antibody combinations are not needed for monoclonal antibody products targeting SARS-CoV-2 proteins, so monoclonal antibody products can be evaluated separately in toxicology studies. If a sponsor evaluates monoclonal antibody products in combination, FDA recommends using the same ratio intended for clinical administration.
We are targeting a protein right? so that should simplify the process if they are looking to combo it with something ...or did I understand that wrong?